KMTS: financial statements from SEC — TradeAlmanac

KMTS

Kestra Medical Technologies, Ltd.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024
Revenue	25m	23m	19m	15m	15m	13m
Cost of revenue	12m	11m	11m	9m	9m	9m
Gross profit	13m	11m	9m	7m	6m	4m
Research and development	5m	5m	4m	3m	4m	3m
Selling, general and administrative	43m	38m	34m	24m	21m	19m
Operating expenses	48m	43m	38m	27m	25m	23m
Operating income	−35m	−32m	−29m	−21m	−19m	−18m
Pre-tax income	−34m	−33m	−26m	−22m	−21m	−20m
Income tax	35,000	34,000	33,000	18,000	8,000	7,000
Net income	−34m	−33m	−26m	−22m	−21m	−20m
Earnings per share	−0.61	−0.64	−0.50	−1.25	−1.19	−1.12
Earnings per share, diluted	−0.61	−0.64	−0.50	−1.25	−1.19	−1.12
Weighted average shares	56m	51m	51m	20m	20m	20m
Weighted average shares, diluted	56m	51m	51m	20m	20m	20m

Balance sheet

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024	Apr 30, 2024
Cash and equivalents	291m	175m	201m	238m	54m	77m	100m	9m
Receivables	13m	10m	9m

Cash flow

Metric	Jul 31, 2025	Jul 31, 2024
Operating cash flow	−26m	−17m
Depreciation and amortisation	2m	2m
Share-based compensation	5m	377,000
Capital expenditure	8m	7m
Investing cash flow	−8m	−7m
Financing cash flow	−2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)